(Date:11/24/2009)...ecently approved the Promega PowerPlex 16 HS Syste...rating DNA records for the National DNA Index Syst...WEB) -- The FBI recently approved the Promega Pow...participating in, or generating DNA records for, t...y contains more than seven million profiles and ha...
(Date:11/24/2009)...RNewswire-FirstCall/--GenomicHealth,Inc.(Nasdaq: G...xecutiveChairman,willpresentatthe21stAnnualPiperJa...cember1,2009at10:00a.m.ET. ,, Toaccessthelivean...ttheInvestorRelationssectionofGenomicHealth,swebsi...ecttothewebsiteatleast15minutespriortothebeginning...
(Date:11/23/2009)...n a provocative new study, a University of Utah sc...s the major cause of global warming cannot be st...ociety builds the equivalent of one new nuclear po...here will be any substantial near-term departure f...de emission rates," says the new paper by Tim Garr...
(Date:11/23/2009)...swire-FirstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;...identifiesandadvancesadiverseportfolioofpromisingc...todayreportedthatCytopia(ASX:CYT)hascommencedenrol...lly-administeredJAK1/JAK2inhibitor.Thetrialisbeing...altomergeCytopiaintoYMhasbeenpreviouslyannouncedan...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Genomic Health to Present at Piper Jaffray Health Care Conference 2Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4...e Market Share Away from Lucentis from 2012 to 201...es , , WALTHAM, Mass., March 10 Decision Resourc...ry firms for pharmaceutical and healthcare issues,... age-related macular degeneration (AMD) market thr...e of Genentech/Novartis Ophthalmics, Lucentis in E...
..., Inc. (Nasdaq: NXTM ), a leading manufacturer o...at Jeffrey H. Burbank, Chief Executive Officer, wi...ual Healthcare Conference on Monday, March 16, 200... NxStage,s investor presentation is scheduled for ...the audio webcast of the presentation, please visi...
...er Key Regulatory Milestone , , LONDON, March 10 ...development in breeding and biotechnology has cont...e for the company,s Seeds and Genomics segment sin...eete, Monsanto,s Vice President of International C...presentation at the Credit Suisse 14th Annual Glob...
Other Biology Technology:Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3NxStage to Present at the Cowen and Company 29th Annual Healthcare Conference 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3...it I provides reagents and a protein standard for ...of reducing agents and detergents. The RC DC prote... reagents and standards sufficient for 500 standar...I, 250 ml alkaline copper tartrate solution, 2 L d...
Gelatin from bovine skin from Sigma-Aldrich
...-the-art separation system using the asymmetric fl...Eclipse integrates easily with Wyatts multi-angle ...N Tristar, as well as the Optilab DSP. The combine...tributions of the particles/molecules separated by...
... for determining the absolute count of CD34+ cells...pheral blood samples, and leukapheresis samples. T...leated cell count and a total CD45 (leucocyte) cel...ocount progenitor cell enumeration system. Specie...
Biology Products: